US Biosimilar Market Formation Isn't Going According To FDA's Plan
This article was originally published in SRA
Executive Summary
As user fee negotiations begin, the US Food and Drug Administration has far more biosimilar sponsors in product development phase and far fewer marketing applications than anticipated.